X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
https://www.ema.europa.eu/en/news/ulipristal-acetate-uterine-fibroids-ema-recommends-restricting-use#:~:text=Ulipristal%20acetate%20for%20uterine%20fibroids%3A%20EMA%20recommends%20restricting%20use,-Share&text=EMA's%20human%20medicines%20committee%20(CHMP,cases%20of%20serious%20liver%20injury.
https://www.reuters.com/article/us-abbvie-fibristal/abbvie-withdraws-uterine-fibroids-drug-from-canada-idUSKBN26L3FS?rpc=401&
https://www.reuters.com/article/us-abbvie-fibristal/abbvie-withdraws-uterine-fibroids-drug-from-canada-idUSKBN26L3FS?rpc=401&
https://www.pharmacompass.com/pdf/news/health-canada-issues-recall-of-allergan-canadas-fibristal-5mg-1601354916.pdf
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/73939a-eng.php#:~:text=In%20a%202018%20safety%20review,to%20implement%20new%20safety%20measures.
https://www.europeanpharmaceuticalreview.com/news/127776/ema-safety-committee-recommends-withdrawal-of-ulipristal-acetate-marketing-authorisation/
https://www.raps.org/news-and-articles/news-articles/2020/9/ema-recommends-pulling-ulipristal-acetate-for-fibr
https://www.fiercepharma.com/pharma/following-years-turmoil-and-resistance-allergan-preparing-to-split-analyst
https://www.fiercebiotech.com/biotech/myovant-hits-goal-uterine-fibroid-phase-3-teeing-up-abbvie-showdown
https://www.fiercepharma.com/pharma/hedge-funder-david-tepper-unhappy-allergan-s-leadership-calls-split-to-ceo-and-chairman
https://www.reuters.com/article/us-allergan-esmya/health-canada-places-restrictions-on-allergans-fibroid-treatment-esmya-idUSKCN1P51UO
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/68806a-eng.php
https://www.fiercepharma.com/pharma/abbvie-s-orilissa-makes-its-uterine-fibroids-case-double-phase-3-win
http://www.pmlive.com/pharma_news/abbvie_preps_uterine_fibroid_filing_after_phase_3_win_1260412
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/005017/WC500254841.pdf
https://pharmaphorum.com/news/fda-rejects-allergans-fibroids-drug-citing-liver-safety-concerns/
https://endpts.com/with-allergans-rival-on-the-regulatory-ropes-abbvie-posts-more-promising-late-stage-data-for-elagolix/
https://www.fiercepharma.com/pharma/fda-rejection-for-allergan-s-esmya-dents-women-s-health-sale-prospects
https://endpts.com/fda-turns-thumbs-down-on-allergans-optimistic-case-for-uterine-fibroid-drug-sends-researchers-back-to-the-drawing-board-on-safety/
https://www.reuters.com/article/allergan-fda/update-1-fda-rejects-allergans-esmya-fibroid-treatment-idUSL3N1VC5I9
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/08/news_detail_003002.jsp&mid=WC0b01ac058004d5c1
http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/005017/WC500251150.pdf
http://www.pharmatimes.com/news/car-t_therapies_leap_towards_eu_approval_1242660
https://www.fiercepharma.com/pharma/watch-out-allergan-billionaire-david-tepper-won-approval-to-push-a-shakeup
https://www.newswire.ca/news-releases/information-update---health-canada-to-conduct-review-of-a-new-potential-safety-risk-of-fibristal-ulipristal-acetate-a-medication-used-to-treat-fibroids-676961383.html
https://www.fiercebiotech.com/biotech/fda-pushes-back-pdufa-date-allergan-s-uterine-fibroid-drug
http://www.pmlive.com/pharma_news/mhra_suspends_new_prescriptions_of_fibroid_drug_esmya_1223141
http://www.pharmatimes.com/news/new_prescriptions_of_allergans_esyma_on_hold_1222859
https://www.fiercepharma.com/pharma/no-new-patients-for-allergan-s-esmya-ema-advises-amid-liver-damage-probe
https://www.prnewswire.com/news-releases/allergan-presented-new-phase-3-data-of-ulipristal-acetate-in-women-with-uterine-fibroids-at-the-american-society-for-reproductive-medicine-annual-congress-300546608.html
http://www.pmlive.com/pharma_news/cdc_backs_gsks_shingrix_over_merck_and_cos_zostavax_1209729
http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207952
http://www.pmlive.com/pharma_news/allergan_plans_to_file_oral_uterine_fibroid_drug_in_us_by_year-end_1184383
http://www.prnewswire.com/news-releases/allergan-and-richter-announce-positive-phase-iii-results-for-ulipristal-acetate-5-and-10-mg-in-the-treatment-of-uterine-fibroids-300264806.html
http://www.pharmatimes.com/Article/16-03-23/SMC_allows_wider_use_of_Gedeon_Richter_s_Esmya.aspx
http://www.fiercebiotech.com/story/allergans-depression-drug-bags-breakthrough-tag-way-phase-iii/2016-01-29
http://www.pmlive.com/news/marketing/2016/january/golin_health_wins_hra_pharma_and_atlantis_healthcare_accounts_917928
http://www.prnewswire.co.uk/news-releases/full-results-of-pearl-iv-study-presented-at-the-european-society-of-gynaecological-endoscopy-esge-congress-confirms-the-efficacy-of-ulipristal-acetate-5-mg-for-the-long-term-management-of-uterine-fibroids-531589331.html
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/04/news_detail_002310.jsp&mid=WC0b01ac058004d5c1
Market Place
Share 
